Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ

Phathom Pharmaceuticals, Inc.

FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).
Over 300,000 filled prescriptions launch-to-date, up ~110% since last earnings report.
Q4 net loss $74.5M; non-GAAP adjusted net loss $56.4M vs $46.0M in prior year Q4.
SG&A expenses rose to $290.7M in FY2024 vs $117.9M in FY2023 due to commercial buildout.
Phase 2 EoE trial for VOQUEZNA to begin enrollment in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.